AIM IMMUNOTECH INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $88.0K | $170.0K | $202.0K | $141.0K | $135.0K | $163.0K | $140.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $3.9M | $6.2M | $10.9M | $7.0M | $7.7M | $5.7M | $4.7M |
| SG&A Expense | — | $7.7M | $13.7M | $21.1M | $13.1M | $8.7M | $8.7M | $7.0M |
| Operating Income | — | $-11.7M | $-19.8M | $-31.9M | $-19.9M | $-18.8M | $-15.2M | $-12.4M |
| Operating Margin | — | -13,254.5% | -11,630.6% | -15,800.0% | -14,129.8% | -13,954.1% | -9,295.7% | -8,887.9% |
| Interest Expense | — | $812.0K | $585.0K | — | — | $67.0K | $672.0K | $427.0K |
| Pretax Income | — | $-14.0M | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-14.0M | $-17.3M | $-29.0M | $-19.4M | $-19.1M | $-14.4M | $-9.4M |
| Net Margin | — | -15,861.4% | -10,188.2% | -14,337.6% | -13,790.8% | -14,168.1% | -8,834.4% | -6,717.1% |
| EPS (Basic) | — | $-8.62 | $-10.31 | $-0.20 | $-0.13 | $-0.13 | $-0.15 | $-0.86 |
| EPS (Diluted) | — | $-8.62 | $-10.31 | $-0.20 | $-0.13 | $-0.13 | $-0.15 | $-0.86 |
| Shares Outstanding (Basic) | 8.1M | 1.6M | 1.7M | 145.8M | — | 144.0M | 126.5M | 31.2M |
| Shares Outstanding (Diluted) | 8.1M | 1.6M | 1.7M | 145.8M | 144.1M | 144.0M | 126.5M | 31.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |